RespireRx Pharmaceuticals Inc

RespireRx Pharmaceuticals — Investor Presentation (January 2017)

41 slides from RespireRx Pharmaceuticals's investor presentation, Jan 6, 2017

  1. Slide 1: Medicines for Respiratory Diseases

    Pharmaceuticals Inc James S. Manuso, Ph.D., President & CEO Medicines for Respiratory Diseases

  2. Slide 2: Forward Looking Statements

    Forward Looking Statements RespireRx Pharmaceuticals Inc The matters discussed in this presentation that are not historical facts are "forward- ooking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and we intend that

  3. Slide 3: Breath

    Breath RespireRx "Breath is the universal factor of life. We are born the first time we inspire, and we die the last time we expire. Breath is life itself. In Sanskrit the same word means both breath and life." ween Abbot George Burke

  4. Slide 4: Innovative Medicines for Respiratory Diseases

    Innovative Medicines for Respiratory Diseases RespireRx Pharmaceuticals Inc Cannabinoids — Dronabinol - Phase 3 ready for Obstructive Sleep Apnea (OSA) Ampakines — CX1739 & CX717 — 4 successful Phase 2A proof of concept trials for Central Sleep Apnea (CSA) and opioid induced respiratory depression (

  5. Slide 5: Sleep Apnea: A National Health Epidemic

    Sleep Apnea A National Health Epidemic as Pharmaceu ticals Inc

  6. Slide 6: Sleep Apnea: A National Health Epidemic

    Sleep Apnea: A National Health Epidemic RespireRx Pharmaceuticals Inc Over 35 Million Americans Stop Breathing Every Night From 5 — 50 Times Per Hour This Is Not Merely Snoring

  7. Slide 7: Sleep Apnea Definitions

    Sleep Apnea — Definitio RespireRx DEFINITIONS + Apnea — Cessation of breathing for > 10 seconds + Hypopnea - Abnormal severe slowing of breathing for > 10 seconds * Apnea - Hypopnea Index (AHI) - used to indicate the severity of sleep apnea. AHI is the average number of apnea-hypopnea events per hou

  8. Slide 8: Three Types of Sleep Apnea

    RespireRx Pharmaceuticals Inc Three Types of Sleep Apnea * Obstructive - a peripheral phenomenon that occurs when throat muscles intermittently relax and block airway during sleep. OSA may be accompanied by snoring * Central - a brain-mediated phenomenon that occurs when breathing control centers in

  9. Slide 9: Company Focus: Apneas

    Company Focus: Apneas RespireRx ¢ Dronabinol for Obstructive Sleep Apnea e Ampakines to address: Post-surgical Central Sleep Apnea Chronic Central Sleep Apnea Spinal Cord Injury Related Apnea

  10. Slide 10: Respiratory Diseases Product Pipeline

    Respiratory Diseases Product Pipeline RespireRx Pharmaceuticals Inc Compound | Indication Preclinical Phase 1 Phase 2 Obstructive Sleep Dronabinol ‘Apnea —— Chronic CSA ————— Post-surgical CSA Opivid-induced RD CX717 Spinal Cord Injury cx1942 Drug-induced RD —7 (injectable) CX1739 10

  11. Slide 11: Dronabinol: Breakthrough Treatment for Obstructive Sleep Apnea

    Dronabinol: Breakthrough Treatment for Obstructive Sleep Apnea ae RespireRx Pharmaceul ticals Inc 11

  12. Slide 12: Obstructive Sleep Apnea: Epidemiology

    Obstructive Sleep Apnea: Epidemiology A) RespireRx Pharmaceuticals Inc U.S Adult Population 245.2M 112% Prevalence OSA (AHI>5) 29.4M 80% 20% Undiagnosed = Diagnosed 235M 5.9M oe -er— Source: Primary research with experts, US, Census (2014), Peppard increased Prevalenceof Sleep-disordered Breathing i

  13. Slide 13: OSA - Scope of the Problem in the US

    OSA - Scope of the Problem in the US RespireRx Pharmaceuticals Inc Estimated Annual Estimated Annual Indicated Drug Disease State US Prevalence Cost to Society Therapy Expenditures OsAts 29.4 Million $162.0 Billion $0 Asthma®? 16.4 Million $18.3 Billion $13.5 Billion Hypertension®1° 43.2 Million $73

  14. Slide 14: Dronabinol: A Breakthrough Treatment for OSA

    rough Treatment for OSA RespireRx Pharmaceuticals Inc nabinol: A Brea * Dronabinol Background = FDA approved for the treatment of anorexia in AIDS patients and nausea and vomiting in cancer patients undergoing chemotherapy (Marinol®) = Schedule Ill drug available by prescription, with a low risk of

  15. Slide 15: Current Approved Treatments

    RespireRx Pharmaceuticals Inc. Current Approved Treatments CPAP device Surgery Dental devices Exercises Stimulants for next day sleepiness Ob ON CPAP is the Standard Treatment for OSA * 30% of patients prescribed CPAP never initiate treatment ‘ 7 a Cy ye eZ * Over 50% of patients stop using CPAP in

  16. Slide 16: Successful Phase 2B PACE Trial in OSA

    Successful Phase 2B PACE Trial in OSA RespireRx Six week, double-blind, placebo controlled Clinical study in patients with OSA Doses: Placebo, 2.5 mg and 10 mg at night Conducted by University of Illinois at Chicago and Northwestern University Fully funded by NIH - >$5 million 16

  17. Slide 17: Successful Phase 2B PACE Trial in OSA

    Successful Phase 2B PACE Trial in OSA RespireRx ¢ 56 evaluable patients completed study = Placebo, n= 17 = 2.5 mg dronabinol, n = 19 * 10 mg dronabinol, n = 20 ¢ Results revealed a statistically significant improvement in Primary Outcome Measures: = Apnea-Hypopnea Index (AHI) (2.5 and 10 mg)! = ESS

  18. Slide 18: PACE Phase 2B Clinical Trial: OSA After Weeks of Dronabinol Treatment

    PACE Phase 2 Clinical Trial: R R OSA After 6 Weeks of Dronabinol Treatment RespireRx 35 p=.02 30 p= .0001 25 = 20 il [ | 15 10 5 Placebo 2.5 mg Apnea-Hypopnea Index (AHI) 18

  19. Slide 19: PACE Phase 2B Trial Compared to Phase 2A

    PACE Phase 2B Trial Compared to Phase 2A RespireRx Pharmaceuticals Inc x= < x ** p<.02, compared to placebo for Phase 2A o 3a 45 5 # +% + o 3 © 30 5 25 Oo 20 2 >} Phase 2A* xr 10 eo 5 PACE Phase 2B o© 0 5. Placebo 2.5 mg 10 mg < * Double blind, placebo controlled dose-ascending study in patients wit

  20. Slide 20: Dronabinol Phase 3 Regulatory Strategy

    Dronabinol — Phase 3 Regulatory Strategy GQ RespireRx - Meet with FDA during mid-2017 - Finalize the Phase 3 trial plan required for approval - Agree ona Special Protocol Assessment (“SPA”) - Seek breakthrough and fast track designation - Accelerate the development path 20

  21. Slide 21: Protecting Dronabinol in the Market

    Protecting Dronabinol in the Market RespireRx ¢ Method-of-Use patent for dronabinol in OSA - Expires in 2025 * Schedule III drug: off-label use monitored by US government, discouraging generic manufacturers from selling off-label ¢ Off-label use of generics and medical marijuana are not covered by i

  22. Slide 22: The Dronabinol Opportunity

    The Dronabinol Opportunity RespireRx Pharmaceuticals Inc Impact on Patient Commercial Opportunity First medicine available for OSA Ease of Use/Better Patient Compliance Low cost Safe and effective Potential for better cardiovascular outcomes Changes the nature of OSA treatment Broadly expands prescr

  23. Slide 23: Potential Dronabinol Economics

    Potential Dronabinol Economics RespireRx If FDA approves dronabinol for the treatment of OSA: ° Initial target market: Mild to moderate OSA patients who are diagnosed but do not use CPAP * 1,770,000 adults (i.e., 30% of 5.9 million diagnosed adults). * Daily price per pill is $5.00 * Patient complia

  24. Slide 24: Ampakines for Opioid Induced Apneas

    Ampakines for Opioid Induced Apneas 24

  25. Slide 25: Chronic Opioid Use and Central Sleep Apnea

    Chronic Opioid Use and Central Sleep Apnea RespireRx Opioid Epidemic » U.S. pharmacies annually dispense 245 million Rx for opioid pain relievers » 10-11 million patients in the US on chronic opioid therapy for pain Opioid induced respiratory depression is manifested as CSA >50% of Chronic Opioid Us

  26. Slide 26: Post-surgical Central Sleep Apnea: Outcomes

    Post-surgical Ce | Sleep Apnea: Outcomes RespireRx Pharmaceuticals Inc Length of Stay (days) Mortality Rate (%) Hospital Costs ($ 70 ea 20 18 billions) 16 60 15 4 50 2 10 10 “0 8 30 5 6 - : ‘B_é:H eo With Respiratory Without Respiratory 0 0 Depression Depression With Respiratory Without With Respira

  27. Slide 27: Ampakines for CSA

    Ampakines for CSA RespireRx Current CSA Treatments * No medicine or device is approved for CSA * CPAP is contra-indicated Ampakines for CSA * Post-surgical CSA produced by opioid pain management Short term use (<1 week) * CSA caused by opioid use in patients with chronic pain Chronic use - longer te

  28. Slide 28: Translational Approach to Respiratory Disorders

    Translational Approach to Respiratory Disorders = Brain stem nuclei that regulate breathing AMPAKINE 100 pA ‘50me Dose C1739 (mglkg Lv) RespireRx Pharmaceuticals Inc contain opiate and AMPA _ glutamate receptors that inhibit and excite cell activity, respectively Ampakines act as_ positive, alloster

  29. Slide 29: Development Status of the Ampakines

    Development Status of the Ampakines Gd RespireRx * CX1739 = Successfully completed four Phase 1 Safety Trials = Successfully completed Phase 2A Trial in opioid-induced respiratory depression = Successfully completed Phase 2A Trial in CSA * CX717 = Successfully completed multiple Phase 1 Safety Trial

  30. Slide 30: Ampakines Reduce Opioid Induced Respiratory Depression in Phase 2A Clinical Trials

    Ampakines Reduce Opioid Induced Respiratory R R Depression in Phase 2A Clinical Trials RespireF X. s gs ge Placebo CX717 Placebo CX1739 é 8 1500 mg 900 mg 2s S*= 0 —j — = i BS — = i i— £5 5 5 10 ee .- ae Z $5 F [ p<.01 Ze 25 £2 £& 20 ze y Be 35 Bz 40 fo} pakines reduce opioid induced respiratory dep

  31. Slide 31: CX1739: Phase 2A Trial in Central Sleep Apnea

    RespireRx Pharmaceuticals Inc CX1739: Phase 2A Trial in Central Sleep Apnea Single Dose Proof of Concept WN Design Randomized, double-blind, placebo-controlled study Population 20 adults with all types of moderate to severe sleep apnea (16 given CX1739; 4 given Placebo) Dosing Each subject received

  32. Slide 32: CX1739 Reduces Apnea-Hypopnea Index in Patients With Mixed and Central Sleep Apneas

    CX1739 Reduces Apnea-Hypopnea Index in Patients With Mixed and Central Sleep Apneas RespireRx Pharmaceuticals Inc Obstructive Apneas Mixed Apneas Central Apnea PA 36 6 S 12, 5 5 3 = 9 = 6 = 3 o g % g 4 2 8. a 20. g s ° 2 3. a 6 & 6. & > = = = ao z2 = 4. 6 6 s a o a 5 5 : Co & ; S S to to zo = NS N a

  33. Slide 33: Ampakine Indications and IP

    Ampakine Indications and IP CG’ RespireRx * Targeted Indications = Post-surgical, opioid-induced CSA = Chronic CSA * Spinal cord injury = Combination formulation with an opioid for treatment of chronic pain * Intellectual Property Protection (owned and licensed) = Issued Composition-of-Matter Patent

  34. Slide 34: Summary

    Summary aa 5: dial lt etd Inc 34

  35. Slide 35: Respiratory Diseases Product Pipeline

    Respiratory Diseases Product Pipeline RespireRx Pharmaceuticals Inc Compound | Indication Preclinical Phase 1 Phase 2 Obstructive Sleep Dronabinol ‘Apnea —— Central Sleep Apnea ————— Post-surgical Apnea Opivid-induced RD CX717 Spinal Cord Injury cx1942 Drug-induced RD —7 (injectable) CX1739 35

  36. Slide 36: RespireRx Pipeline: Ongoing Development

    RespireRx Pipeline: R ireR Treatments for Multi $Billion Respiratory Markets prespane® x Ongoing Development Dronabinol - OSA - Preparing for FDA meeting to request: * Special Protocol Assessment (“SPA”) to finalize the Phase 3 program * Fast Track Designation * Breakthrough Designation Ampakines —

  37. Slide 37: Development Milestones

    Development Milestones RespireRx Pharmaceuticals Inc 1Q2017_ 2Q2017_ —3Q2017_ — 4Q2017_—: 12018 2Q2018 Dronabinol FDA Regulatory - Prepare and submit SPA Pivotal Clinical Trial Proprietary Extended Release Formulation Development CX1739 FDA Regulatory - Prepare and submit IND Central Sleep Apnea Cli

  38. Slide 38: Capital Structure and Market Metrics

    Capital Structure (rounded) . and Market Metrics - UPDATED) oe on mre Pro Forma at December 31, 2016 Common Stock (includes 130,000 shares issued on Dec 29 and 30, 2,149,000 2016 Common Stock Equivalents of Convertible Notes 29,000 Common Stock Equivalents of all Options and Warrants Granted (includ

  39. Slide 39: Management and Directors

    Management and Directo RespireRx James Manuso President, CEO & Vice Chairman Arnold Lippa CSO & Executive Chairman Jeff Margolis VP, Secretary/Treasurer, Director Robert Weingarten CFO, Director Richard Purcell Senior VP, R& D Katie MacFarlane Director Senior VP, Napo Pharmaceuticals James Sapirstei

  40. Slide 40: Innovative Medicines for Respiratory Diseases

    Innovative Medicines for Respiratory Diseases RespireRx Pharmaceuticals Inc Cannabinoids — Dronabinol - Phase 3 ready for Obstructive Sleep Apnea (OSA) Ampakines — CX1739 & CX717 — 4 successful Phase 2A proof of concept trials for Central Sleep Apnea (CSA) and opioid induced respiratory depression (

  41. Slide 41: RespireRx Pharmaceuticals Inc

    Pharmaceuticals Inc James S. Manuso, Ph.D., President & CEO Medicines for Respiratory Diseases

RespireRx Pharmaceuticals — Investor Presentation (January 2017) on 6ix